OLMA Live signals | Maximize Profits with Getagraph.com

BUY 106580 min ago

@ $15.41

Issued: 14 Feb 2024 @ 11:19

Return: -35.43%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -3.51 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers...

Stats
Today's Volume	420 674
Average Volume	823 114
Market Cap	556.35M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.530 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.65
ATR14	$0.0180 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Harmon Cyrus	Sell	20 000	Common Stock
2024-03-18	Zojwalla Naseem	Sell	13 700	Stock Option (Right to Buy)
2024-03-18	Zojwalla Naseem	Buy	13 700	Common Stock
2024-03-05	Rappaport Andrew	Buy	385 965	Common Stock
2024-03-05	Rappaport Andrew	Sell	481 014	Common Stock

INSIDER POWER
66.27
Last 96 transactions
Buy: 6 282 820 \| Sell: 988 788

Volume Correlation

Long: 0.12 (neutral)

Short: -0.11 (neutral)

Signal:(45.679) Neutral

Olema Pharmaceuticals, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Olema Pharmaceuticals, Correlation - Currency/Commodity

-0.25
( neutral )

-0.34
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.00
( neutral )

0.64
( weak )

Olema Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-377 000 (0.00 %)
EPS:	$-2.14

FY	2023
Revenue:	$0
Gross Profit:	$-377 000 (0.00 %)
EPS:	$-2.14

FY	2022
Revenue:	$0
Gross Profit:	$-1.66M (0.00 %)
EPS:	$-2.56

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.795

Financial Reports:

No articles found.

Olema Pharmaceuticals,

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.